Clinicians managing women across primary, cardiology, gynaecology, and endocrine services encounter the interplay between sex hormones and cardiovascular risk daily. Premenopausal women benefit from oestrogen’s effects on vascular tone, lipids, and inflammation, contributing to lower coronary disease rates compared with age-matched men. This advantage diminishes post-menopause, with accelerated risk increase linked to hormonal shifts, particularly in cases of premature or surgical menopause.
Pregnancy complications (pre-eclampsia, gestational hypertension, gestational diabetes, peripartum cardiomyopathy) serve as sex-specific risk enhancers. NICE and MBRRACE-UK emphasise integrating these into lifetime risk assessment and ensuring postnatal follow-up. HSSIB reports highlight diagnostic delays when women’s presentations – often involving fatigue, breathlessness, or jaw pain – are attributed to non-cardiac causes.
NG23 and HRT in context
NICE guideline NG23 (Menopause: identification and management) states that combined or oestrogen-only HRT should not be offered for primary or secondary prevention of cardiovascular disease.
For vasomotor symptom management in women under 60 or within 10 years of menopause without contraindications, HRT can be considered with shared decision-making.
Non-oral routes and lowest effective doses are often preferred where cardiovascular concerns exist.
Guidance emphasises individual assessment, including personal and family history.
Clinical actions
- Integrate full reproductive history (pregnancies, menopause timing, hormonal treatments) into cardiovascular records.
- Apply sex-specific symptom awareness to reduce misattribution.
- Coordinate across specialties for women on contraception, HRT, or endocrine therapies.
- Monitor modifiable risks aggressively during perimenopause and post-pregnancy.
British Menopause Society resources and evolving NHS pathways support these approaches. Historical trial underrepresentation of women continues to inform the need for cautious, evidence-based application.HRT is not indicated for cardiovascular prevention.
NICE guidance states that combined or oestrogen-only HRT should not be offered for primary or secondary CVD prevention. For symptom relief in women under 60 or within 10 years of menopause without contraindications, appropriately timed and formulated HRT carries a favourable profile for many. Non-oral routes may be preferred in those with risk factors. Shared decision-making is essential, especially with established CVD.
Clinical watchpoints
- Document pregnancy and reproductive history in cardiovascular records.
- Consider endocrine disorders (PCOS, thyroid disease) and autoimmune conditions that disproportionately affect women.
- Use sex-specific symptom recognition training to reduce misattribution.
- Ensure seamless transitions between maternity, menopause, and cardiology services.
Emerging NHS England pathways and British Cardiovascular Society statements support greater attention to these factors.
Historical underrepresentation of women in cardiovascular trials has limited generalisability; contemporary datasets are improving but still require vigilance.
See related clinical pages: Informed Consent in Women’s Cardiovascular Care and Patient Safety in Hormonal Transitions.
References
- NICE NG23 Menopause guideline.
- British Menopause Society guidance on menopause in women with CVD.
- MBRRACE-UK reports.
- BHF women’s heart health resources.
- HSSIB investigations.
Mandatory disclaimer
This article is for general information and discussion only. It is not medical or legal advice, nor a substitute for professional advice. To contribute evidence, ideas, or corrections, please email womenshealthproject@outlook.com. Please do not share personal data when emailing. Individual cases cannot be reviewed.
This project does not offer any form of legal service and cannot assist with complaints, claims or individual advocacy. This platform is independent and not affiliated with any law firm, regulator, inquiry or clinical body.
© 2026 Women’s Health Inquiry Project (WHIP). This article includes original analysis of material from publicly available national sources. It may not be reproduced without permission.